About
Cizzle Biotechnology is developing a blood test for the early detection of a majority of the different forms of lung cancer. Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of C1Z1 known as CIZ1B. C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is highly correlated with early stage lung cancer.
Technologies
Google Tag ManagerUbuntuWordPress.orgreCAPTCHAWoo CommerceApacheMobile FriendlyShutterstock
Keywords
precision diagnosticsstrategic partnershipscost-effective diagnosticshealthcared2cbiotechnologyglobal healthcare solutionsmedical researchbiomarker validationnon-invasivepatient outcomesearly lung cancer detectionblood plasma testingresearch and development in the physicalengineeringand life sciencesclinical validationdiagnostic pathwayproprietary immunoassayblood testregulatory approvalciz1b variantbiomarker detectionhigh sensitivity detectionb2bnon-invasive blood testearly detectioncancer survivalmedical diagnosticsciz1 protein
Company Information
- Employees4
- Founded2001
- Total Funding$440227
Location
London, United Kingdom
